148 related articles for article (PubMed ID: 2129413)
41. Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation.
Duboscq C; Genoud V; Parborell MF; Kordich LC
Thromb Res; 1997 Jun; 86(6):505-13. PubMed ID: 9219330
[TBL] [Abstract][Full Text] [Related]
42. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
43. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
44. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
Onundarson PT; Francis CW; Marder VJ
J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
[TBL] [Abstract][Full Text] [Related]
45. [Profibrinolytic activity of recombinant hirudin?].
Tsakiris DA; Meyer D; Fabbri J; Close P; Marbet GA
Schweiz Med Wochenschr; 1991 Mar; 121(10):338-40. PubMed ID: 2028237
[TBL] [Abstract][Full Text] [Related]
46. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Kajimoto Y; Ohta T; Kuroiwa T
Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
[TBL] [Abstract][Full Text] [Related]
47. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin.
Bode C; Hudelmayer M; Mehwald P; Bauer S; Freitag M; von Hodenberg E; Newell JB; Kübler W; Haber E; Runge MS
Circulation; 1994 Oct; 90(4):1956-63. PubMed ID: 7923685
[TBL] [Abstract][Full Text] [Related]
48. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
49. Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy.
Rudd MA; George D; Johnstone MT; Moore RT; Collins L; Rabbani LE; Loscalzo J
Circ Res; 1992 Apr; 70(4):829-34. PubMed ID: 1551206
[TBL] [Abstract][Full Text] [Related]
50. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
51. Fibrin degradation products generation and fibrinopeptide A release in normal plasma incubated with thrombolytic agents: proposed mechanisms.
Mirshahi M; Soria J; Bertrand O; Amiral J; Soria C
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):531-6. PubMed ID: 1723308
[TBL] [Abstract][Full Text] [Related]
52. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
Graham DA; Huang TC; Keyt BA; Alevriadou BR
Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
[TBL] [Abstract][Full Text] [Related]
53. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
[TBL] [Abstract][Full Text] [Related]
54. Comparison of affinities of urokinase and tissue plasminogen activator for fibrin clots.
Homandberg GA; Wai T
Thromb Res; 1989 Aug; 55(4):493-501. PubMed ID: 2510355
[TBL] [Abstract][Full Text] [Related]
55. The effect of flow on lysis of plasma clots in a plasma environment.
Sakharov DV; Rijken DC
Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
[TBL] [Abstract][Full Text] [Related]
56. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
[TBL] [Abstract][Full Text] [Related]
57. Southern copperhead venom enhances tissue-type plasminogen activator induced fibrinolysis but does not directly lyse human plasma thrombi.
Nielsen VG
J Thromb Thrombolysis; 2016 Jul; 42(1):33-7. PubMed ID: 26407681
[TBL] [Abstract][Full Text] [Related]
58. Displacement of fibrin-bound thrombin by r-hirudin precludes the use of 131I-r-hirudin for detecting pulmonary emboli in the rabbit.
Rubens FD; Ross-Ouellet B; Dennie C; Coates G; Kinlough-Rathbone RL; Hatton MW
Thromb Haemost; 1994 Aug; 72(2):232-8. PubMed ID: 7831658
[TBL] [Abstract][Full Text] [Related]
59. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
60. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
Reilly CF; Fujita T; Hutzelmann JE; Mayer EJ; Shebuski RJ
Circulation; 1991 Jul; 84(1):287-92. PubMed ID: 1905594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
